Mrs J, aged 81 years with hypertension and hyperlipidemia, requested a referral to a neurologist, stating: "I am forgetting things I just heard."
Methods
We searched PubMed for English-language articles in peerreviewed journals from inception through July 2014 using MeSH terms: mild cognitive impairment/diagnosis OR mild cognitive impairment/treatment OR mild cognitive impairment/therapy. We also searched the Cochrane Library database for mild cognitive impairment; we reviewed the updated 2011 National Institute on AgingAlzheimer's Association (NIA-AA) diagnostic guidelines for dementia, 1 MCI, 2 and preclinical Alzheimer disease. 3 Additionally, we reviewed a recent analysis of diagnostic testing for Alzheimer disease from the Institute for Clinical and Economic Review, 4 and a Centers for Medicare & Medicaid Services decision memo regarding β-amyloid (Aβ) positron emission tomography (PET) imaging for dementia. 5 Our PubMed search yielded 4977 unique articles and our Cochrane Library search yielded 22 systematic reviews-the titles and abstracts of which were examined for relevance. For each of the relevant articles identified, we then screened the references and checked related citations in PubMed. Randomized double-blind placebo-controlled trials with results reported as intention-to-treat analyses were considered highest-quality data. Large prospective cohort studies, meta-analyses, and systematic literature reviews were also included as appropriate for supplementing the randomized-controlled trial results. Our results and discussion cite the articles that both authors found most relevant to the diagnosis and management of MCI. We developed recommendations using evidence from these sources, as well as our clinical experience.
Definitions and Diagnostic Criteria
In 2011, the NIA-AA convened workgroups to revise the 1984 diagnostic criteria for dementia, as well as dementia due to Alzheimer disease. Diagnostic criteria for MCI, the symptomatic predementia phase of the trajectory of cognitive decline, were subsequently established (Box 1). 2 The key criteria that distinguish MCI from dementia are preservation of independence in functional abilities (ADLs and IADLs) and lack of significant impairment in social or occupational functioning. MCI subtypes are sometimes defined by presence or absence of memory difficulties (amnestic vs nonamnestic MCI) 6 and the number of affected cognitive domains.
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The NIA-AA criteria define MCI due to Alzheimer's disease as "those symptomatic but non-demented individuals whose primary underlying pathophysiology is AD [Alzheimer disease]." 2 MCI due to Alzheimer disease is characterized by memory impairment, longitudinal decline in cognitive function, and lack of evidence for vascular, traumatic, or other medical causes of cognitive decline (Box 1). The NIA-AA guidelines also proposed research criteria for the use of biomarkers-measures of Aβ deposition and of neuronal injury-to further refine the likelihood that a patient's MCI is due to Alzheimer disease, but these tests are not yet recommended for routine clinical use.
Two other recently developed clinical classification systems identify a symptomatic but nondemented stage of cognitive decline, but use different terminology than the NIA-AA criteria. The International Working Group criteria use the terms prodromal AD or predementia AD to refer to individuals with cognitive impairment that is not severe enough to significantly affect ADLs, 7 
while the new Diagnostic and Statistical Manual of Mental
Disorders (Fifth Edition) (DSM-5) refers to this stage as mild neurocognitive disorder.
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Epidemiology and Risk Factors
Recent clinical and population-based samples suggest an MCI prevalence of 10% to 20% for adults aged 65 years and older, 6,9 although lack of standardized diagnostic criteria and differences in sample characteristics across studies have led to significant uncertainty around these estimates. The likelihood that MCI will progress to dementia depends on the specific diagnostic criteria used and All patients with suspected MCI should undergo a comprehensive history and physical examination focusing on cognitive function, functional status, medications, neurological or psychiatric abnormalities, and laboratory testing. The main goals are to distinguish MCI from normal aging or dementia and to identify potentially reversible forms of MCI due to other conditions (eg, depression, medication effects, thyroid disease, and vitamin B 12 /folate deficiency) (Figure) .
Cognitive Function
A history of cognitive changes over time, verified by knowledgeable informants if available, is important for identifying the first diagnostic criterion-decline in cognitive function (Box 2).
14,15 Critical features that may elucidate a cause are onset, trajectory, time course, and nature of the cognitive symptoms. Very rapid cognitive decline (weeks to months) is not typical of MCI due to Alzheimer disease and should raise concerns for other causes such as neoplasm, metabolic disorders, or prion disease (Box 1). Patients and informants (such as family members) may report conflicting views regarding the presence and severity of cognitive symptoms, either from lack of insight or because cognitive decline can be emotionally charged and symptom reporting may be minimized to avoid difficult or disrespectful discussions.
14 Patients with suspected MCI should have cognitive function assessments at baseline and at follow-up visits. A recent US Preventive Services Task Force systematic review on screening for cognitive impairment in older adults examined a number of instruments for primary care settings. 16 The review concluded that brief cognitive assessments can successfully detect dementia in primary care, but the sensitivity of those instruments for detecting MCI is generally lower, and it is still unclear whether early diagnosis of cognitive impairment improves important patient or caregiver outcomes. 23 and using a cut point of 6 points or greater on the Functional Activities Questionnaire was found to have an 85% accuracy rate for distinguishing patients with MCI from those with dementia. 24 Mrs J was still generally independent, but had become slower and less efficient with customary activities (eg, cooking and driving); increasing difficulties with finances may be another sensitive indicator of early cognitive decline.
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Medication Review
Certain classes and combinations of medications can contribute to cognitive impairment 26 so all current prescription and overthe-counter medications should be reviewed. Drug classes most likely to contribute to cognitive impairment include anticholinergics, opiates, benzodiazepines and nonbenzodiazepine hypnotics (eg, zolpidem), digoxin, antihistamines, tricyclic antidepressants, skeletal muscle relaxants, and antiepileptics. Hormonal therapy (estrogen alone or estrogen plus progestin) for menopause has been shown to increase risk for the combined end point of MCI or dementia. 27 In addition, hypotension related to intensive treatment of hypertension 28 and hypoglycemia related to intensive treatment of diabetes 29 may also contribute to cognitive decline.
Neurological and Psychiatric Evaluation
Clinicians should perform a focused review of neurologic and psychiatric symptoms, a complete neurological examination, and a depression assessment in patients with suspected MCI. Review of symptoms should probe vision and hearing problems, sleepdisordered breathing, behavioral or personality changes (which may suggest depression, thyroid disease, or frontotemporal dementia), visual hallucinations (dementia with Lewy bodies or depression with psychotic features), numbness or tingling in the extremities (neuropathy), dizziness upon standing (orthostatic hypotension), changes in speech (stroke or Parkinson disease), and changes in gait (stroke or normal-pressure hydrocephalus). 14 A complete neurological examination, including orthostatic hypotension, extraocular movements, vision, hearing, speech, focal weakness, ability to stand from a chair, and gait is useful for identifying potential contributors to cognitive decline, including stroke, Parkinson disease, normal-pressure hydrocephalus, or neuropathy due to toxins or vitamin deficiency.
14 Depression is associated with cognitive impairment in older adults and the relationship is likely bidirectional. Depression can be screened in older adults using assessment tools such as the Geriatric Depression Scale, on which a score of 6 or greater is suggestive of depression. 30 Clinicians can query the informant about the patient's depressive and behavioral symptoms using the Neuropsychiatric Inventory. We summarize potential interventions for MCI from recent clinical trials ( Table 1 and Table 2 ), systematic reviews, meta-analyses, and observational studies. Participants in MCI clinical trials have often had more education, healthier behaviors, and less comorbidity (including lower ratesofsmoking,hypertension,andheartdisease)comparedwithage- 
Vascular Risk Factor Control
Stroke prevention and vascular risk factor control may reduce risk of progression from MCI to dementia, regardless of radiographic evi- b Behavioral interventions were subcategorized as cognitive intervention, physical activity, multidiciplinary care, or psychotherapeutic intervention studies.
pairment are common, and many MCI patients have pathological evidence of neurodegenerative and cerebrovascular disease. 62 Strategies for primary or secondary stroke prevention include blood pressure control, smoking cessation, statin therapy, antiplatelet therapy, and anticoagulation or antithrombotic therapy for atrial fibrillation.
63,64
Independent of clinical stroke prevention, blood pressure control may reduce dementia risk. In the Systolic Hypertension in Europe (Syst-Eur) trial of 2418 adults (mean age 70 years), treatment of isolated systolic hypertension reduced incidence of dementia by 50% (3.8 vs 7.7 cases per 1000 patient-years; P = .05) over 2 years.
65 A meta-analysis of 4 placebo-controlled trials (16 595 patients) also suggested that antihypertensive treatment may reduce incident dementia (HR, 0.87; 95% CI, 0.76-1.00; P = .045).
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The robustness of the evidence base for antihypertensive therapy to prevent cognitive decline, particularly in the oldest old, is 69 Given that higher variability in systolic blood pressure is associated with stroke, cerebral white matter lesion progression, lower hippocampal volume, and cognitive impairment, clinicians may consider medications that reduce blood pressure variability (calcium channel blockers or thiazide diuretics) when selecting antihypertensive regimens, particularly in patients with marked variability in blood pressure, 70, 71 although this is unsettled. 72 It is important to avoid overtreatment of hypertension and diabetes because hypotension and hypoglycemia may increase the risk of cognitive decline and other patient harms.
28,29
Treatment of the Patient
Although there are no drugs proven or approved to treat MCI, optimizing patients' general medical and functional status, and providing counseling regarding issues such as driving and home safety can maximize patient and caregiver well-being, and reduce risk of negative outcomes (Box 3). Individuals with MCI are at increased risk for gait dysfunction, mobility decline, and falls. 73 Gait assessment, while performing an attention-demanding task (dual-task testing), may identify motor control and performance problems that could benefit from tailored interventions. 73 Optimizing visual and auditory acuity may enhance functioning because untreated vision and hearing problems are associated with cognitive decline. 74, 75 Use of a CPAP (continuous positive airway pressure machine) for patients with sleepdisordered breathing may also reduce risk of progression of cognitive decline, 12 although definitive clinical trials are still necessary.
Although depressive and vegetative symptoms may cause or contribute to MCI, there is mixed evidence as to whether treatment of depression improves cognitive impairment or decreases risk of incident MCI or dementia. Given increasing evidence of the negative impact of anticholinergic medications on cognitive function in older adults, 76 treatment with antidepressants that have significant anticholinergic properties (eg, amitriptyline, nortriptyline, and paroxetine) should be avoided. A trial of withdrawing and simplifying medication regimens in older adults may lead to improvements in cognitive function.
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Counseling on Behaviors There is modest evidence from RCTs and clinical studies that various behavioral interventions, particularly aerobic exercise and mental activity, may have small but beneficial effects on cognitive function in older adults with MCI (Tables 1 and 2) . 16 Several RCTs of community-dwelling adults with or at risk for MCI have shown that home-based or professionally-supervised programs of aerobic exercise or resistance training modestly improve cognition, particularly executive function, over 18-month follow-up ( Table 2 ). The combination of aerobic exercise and mental activity may benefit patients with MCI. The Mental Activity and eXercise (MAX) RCT of 126 inactive older adults with memory concerns demonstrated that a 12-week program of combined physical and mental activity was associated with small significant improvements in global cognitive function, regardless of the types of physical activity (aerobic vs stretching and toning) and mental activity (intensive vs educational videos). 48 Observational studies suggest that the Mediterranean diet also may reduce the risk of converting from MCI to dementia.
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Other observational studies suggest that social engagement may reduce the risk of cognitive decline and preserve memory, particularly in adults with less than 12 years of education or those with vascular disease. 78 Little is known about the effectiveness of multidisciplinary care programs or supportive care interventions (eg, counseling, education, support groups) for patients with MCI or their families because well-designed RCTs are lacking 16 and one RCT that included many patients with dementia showed negative results (Table 1) . 49 A few, small RCTs found that psychotherapy may modestly increase patients' acceptance of an MCI diagnosis and also provide knowledge, insight, acceptance, and coping skills for significant others (Table 2) Existing models to predict risk of MCI progression have limitations, including poor discrimination and low positive predictive values. Overall, better prognostic models are needed that account for demographic, clinical, neuropsychiatric, biological, and pathological heterogeneity in elders at risk for cognitive decline. 90 Competing risks are another important considerationalthough patients with MCI have an increased risk of dementia, they also have greater mortality. Risk-prediction models should estimate the likelihood that MCI patients will develop dementia prior to dying from competing causes, especially cardiovascular disease and cancer. Unfortunately, clinicians currently have insufficient information regarding Mrs J's absolute risk of developing dementia compared with her risks of dying from a nondementia cause or experiencing stable or improved cognition in the next few years.
Future Directions
Older adults fear cognitive decline and most patients prefer testing that would indicate future Alzheimer disease risk. 91 These factors, combined with changes in diagnostic technologies for risk stratification, portend that guidelines for the diagnosis and management of MCI will likely be in flux and debated over the next decade. The limited efficacy of currently available interventions to prevent or delay progression of MCI to dementia 90 increases the importance of clinicians discussing the balance of benefits and risks of interventions, as well as patients' goals and preferences regarding medical interventions in later life. Given that there can be significant financial costs associated with diagnostic testing for MCI, as well as emotional distress and social stigma, some patients and families may prefer to forego the diagnostic evaluation. 92 Clinical decision-making regarding when and how to diagnose and treat MCI (and preclinical Alzheimer disease) will likely change significantly if and when a safe and effective disease-modifying agent for preclinical Alzheimer disease and dementia is identified. In the meantime, primary care clinicians can support patients like Mrs J in practicing healthy lifestyle behaviors, minimizing risks from polypharmacy and comorbidities, and counseling patients and families about how best to plan for the future. 
